VIP EARLY ALERT SERVICE Offered by Elite Traders Group for Limited Time, 11 Positions Remain. Only $29.95/Month or $199.00/Year
June 26 2013 - 8:30AM
InvestorsHub NewsWire
One of the most frequently asked questions is, "does your VIP group
receive alerts ahead of the crowd?" and the answer is YES. We offer
our VIP's early alerts and VIP only alerts that the rest of the
group is not privy to. VIP early alerts and VIP only alerts are
provided via our private VIP twitter feed which is not viewable by
the public. This allows us to keep VIP alerts within our exclusive
group and not accessible by third parties. Other VIP pre-promotion
alert services send by email which goes viral within minutes and
really is not a VIP alert at all. We typically send the new feature
alerts to our premium members 30 minutes to 24 hours in advance.
This gives our VIP's more time to conduct their due diligence and
avoid chasing the price action. Our group is growing at an
exponential rate and this service will be going up in price soon
and eventually closed for good. We currently have 89 VIP's
(verifiable at this twitter link:
https://twitter.com/FPPVIP) and will not exceed
100.
Use the following link now to increase your chances of success.
http://www.firstpennypicks.com/vip-membership/
Cortex Pharmaceuticals, Inc. (
OTCPINK: CORX) discovers, develops, and
commercializes pharmaceuticals for the treatment of
neurodegenerative diseases and other neurological and psychiatric
disorders. The Company develops a family of chemical compounds,
known as Ampakines, that enhance the activity of the AMPA-type
glutamate receptor. For a full technical analysis use the following
link: http://bit.ly/TechnicalReport
XOMA Corporation (
NASDAQ: XOMA), incorporated on November
31, 2011, is engaged in the discovery and development of
antibody-based therapeutics. The Company's lead drug candidate is
gevokizumab (formerly XOMA 052), a humanized monoclonal allosteric
modulating antibody designed to inhibit the pro-inflammatory
cytokine interleukin-1 beta (IL-1 beta). The Company's preclinical
pipeline includes classes of antibodies that activate or sensitize
the insulin receptor in vivo, named XMet, and represent potential
new therapeutic approaches to the treatment of diabetes and several
diseases that have insulin involvement. For a full technical
analysis use the following link: http://bit.ly/TechnicalReport
Star Scientific, Inc. (
NASDAQ: STSI), incorporated on June 24,
1985, is engaged in the manufacturing and production of dietary
supplements. The Company's operating subsidiaries manufacture,
distribute and sell consumer products and dietary supplements. Its
segment includes dietary supplements. Through its Rock Creek
Pharmaceuticals, Inc. (Rock Creek) subsidiary, the Company is
engaged in the manufacture, sale, marketing and development of
non-nicotine nutraceutical, dietary supplements: Anatabloc, for
anti-inflammatory support; the manufacture, sale and marketing of a
cosmetic facial cream, and the development of other nutraceuticals,
dietary supplements and pharmaceutical products. For a full
technical analysis use the following link:
http://bit.ly/TechnicalReport
ARIAD Pharmaceuticals, Inc. (
NASDAQ: ARIA), incorporated on on April
12, 1991, is a global oncology company focused on the discovery,
development and commercialization of medicines for the cancer
patients. ARIAD's first medicine, Iclusig, is approved in the
United States for the treatment of adult patients with chronic,
accelerated or blast phase chronic myeloid leukemia that is
resistant or intolerant to prior tyrosine kinase inhibitor (TKI)
therapy or Philadelphia chromosome-positive acute lymphoblastic
leukemia that is resistant or intolerant to prior TKI therapy. As
of January 11, 2013, additional clinical trials of Iclusig in other
cancers were ongoing. As of January 11, 2013, ARIAD also studied
AP26113, another molecularly targeted medicine, in certain forms of
lung cancer. For a full technical analysis use the following link:
http://bit.ly/TechnicalReport
http://www.Firstpennypicks.com was developed as a
beacon of hope in the micro-cap stock newsletter industry.
We always hand-pick our alerts as opposed to biased advertising.
Our service typically covers the hottest penny stocks for a longer
term than one day offering more potential profit situations.
This is why we are the fastest growing community of micro-cap
traders on the web.
To Receive More Reports like this one Subscribe free at
http://www.FirstPennyPicks.com
For mobile alerts text "FPPALERTS" to 25827
Disclaimer: Firstpennypicks.com is owned by Elite traders Group
LLC. Information, opinions and analysis contained herein are based
on sources believed to be reliable, but no representation,
expressed or implied, is made as to its accuracy, completeness or
correctness. The opinions contained herein reflect our current
judgment and are subject to change without notice. We accept no
liability for any losses arising from an investor's reliance on or
use of this report. This report is for information purposes only,
and is neither a solicitation to buy nor an offer to sell
securities. Certain information included herein is forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements concerning
manufacturing, marketing, growth, and expansion. Such
forward-looking information involves important risks and
uncertainties that could affect actual results and cause them to
differ materially from expectations expressed herein. First Penny
Picks has not been compensated for this report.
SOURCE: Elite Traders Group LLC
Contact: Editor@FirstPennyPicks.com
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Apr 2023 to Apr 2024